Trial · NCT02965027

Prazosin for Post-Concussive Headaches

NCT02965027, Phase 4, Completed, Seattle Institute for Biomedical and Clinical Research; results first posted 2024-07-10

3 sourcestrials-2026-11-12-0.5.0

Download JSON

Cite this record

ConductScience Library. Prazosin for Post-Concussive Headaches. Trials, record NCT02965027. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02965027

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Prazosin for Post-Concussive Headaches
NCT number: NCT02965027
Status: Completed
Phases: Phase 4
Enrollment: 89 participants, actual
Lead sponsor: Seattle Institute for Biomedical and Clinical Research
Conditions: Post-Traumatic Headache
Interventions: Prazosin, Placebo
First posted: 2016-11-16
Last updated: 2024-07-10
Results first posted: 2024-07-10

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change From Baseline in Headache Frequency	baseline, 4,8, and 12 weeks after steady dose	Headache log completed by participant to capture number of headaches experienced.
Secondary	Overall Sleep Quality as Assessed by Pittsburgh Sleep Quality Index	baseline, 4, 8, 12 weeks after steady dose	Overall sleep quality assessed utilizing the Pittsburgh Sleep Quality Index (PSQI). The PSQI contains 19 self-rated questions. The 19 self-rated items are combined to form seven "component" scores, each of which has a range of 0-3 points. The seven component scores are then added to yield one "global" score with a range of 0-21 points, "0" indicating no difficulty and "21" indicating sever difficulty in all areas. Minimum Score = 0 (better); Maximum Score = 21 (worse). Interpretation: TOTAL \< 5 associated with good sleep quality. TOTAL \> 5 associated with poor sleep quality The difference between means is shown for weeks 4, 8 and 12.
Secondary	Insomnia Severity Index	baseline, 4, 8, 12 weeks after steady dose	Insomnia severity assessed using the Insomnia Severity Index (ISI). This 7-item self-report is designed to measure and detect cases of insomnia. Each question is scored on a scale of 0 to 4. The 7 items are added together. Sum scores for items 1-7 0-7 = No clinically significant insomnia 8-14 = Subthreshold insomnia 15-21 = Clinical insomnia (moderate severity) 22-28 = Clinical insomnia (severe) The difference between means is shown for weeks 4, 8 and 12.

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Change From Baseline in Headache Frequency	baseline, 4,8, and 12 weeks after steady dose	headaches per month	MEAN
SECONDARY	Overall Sleep Quality as Assessed by Pittsburgh Sleep Quality Index	baseline, 4, 8, 12 weeks after steady dose	score on a scale	MEAN
SECONDARY	Insomnia Severity Index	baseline, 4, 8, 12 weeks after steady dose	score on a scale	MEAN

Source ClinicalTrials.gov

Results by group24

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Change From Baseline in Headache Frequency	Prazosin	Baseline	16.4	Standard Error 1.2	headaches per month
Change From Baseline in Headache Frequency	Placebo	Baseline	18.5	Standard Error 1.6	headaches per month
Change From Baseline in Headache Frequency	Prazosin	Week 4 - Baseline	-9.2	Standard Error 0.9	headaches per month
Change From Baseline in Headache Frequency	Placebo	Week 4 - Baseline	-7.4	Standard Error 1.2	headaches per month
Change From Baseline in Headache Frequency	Prazosin	Week 8 - Baseline	-9.9	Standard Error 0.9	headaches per month
Change From Baseline in Headache Frequency	Placebo	Week 8 - Baseline	-9.1	Standard Error 1.2	headaches per month
Change From Baseline in Headache Frequency	Prazosin	Week 12 - Baseline	-10.7	Standard Error 0.9	headaches per month
Change From Baseline in Headache Frequency	Placebo	Week 12 - Baseline	-6.9	Standard Error 1.3	headaches per month
Overall Sleep Quality as Assessed by Pittsburgh Sleep Quality Index	Prazosin	Baseline	12.1	Standard Error 0.6	score on a scale
Overall Sleep Quality as Assessed by Pittsburgh Sleep Quality Index	Placebo	Baseline	12.0	Standard Error 0.8	score on a scale

1 to 10 of 24Source ClinicalTrials.gov

See all 24 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Prazosin	59
Overall Study	STARTED	Placebo	30
Overall Study	COMPLETED	Prazosin	52
Overall Study	COMPLETED	Placebo	26
Overall Study	NOT COMPLETED	Prazosin	7
Overall Study	NOT COMPLETED	Placebo	4

Source ClinicalTrials.gov

Adverse events36

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Dizziness (any)	General disorders	Prazosin	37	59	51
other	Dizziness (any)	General disorders	Placebo	6	30	7
other	Dizziness on Standing	General disorders	Prazosin	24	59	30
other	Dizziness on Standing	General disorders	Placebo	1	30	1
other	Lightheadedness	General disorders	Prazosin	28	59	32
other	Lightheadedness	General disorders	Placebo	11	30	11
other	Vertigo	General disorders	Prazosin	1	59	1
other	Vertigo	General disorders	Placebo	1	30	1
other	Nasal Congestion	General disorders	Prazosin	19	59	21
other	Nasal Congestion	General disorders	Placebo	3	30	3

1 to 10 of 36Source ClinicalTrials.gov

See all 36 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Prazosin	0	59
Total, all-cause mortality	Placebo	0	30
Total, other adverse events	Prazosin	52	59
Total, other adverse events	Placebo	22	30
Total, serious adverse events	Prazosin	1	59
Total, serious adverse events	Placebo	1	30

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Prazosin vs Placebo: deaths from any cause	Trial comparisons
Prazosin vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02965027

GET https://conductscience.org/api/trials/v1/NCT02965027/results?page=2

API reference For AI assistants